SCHEMBL5205798

SCHEMBL5205798

COc1cc(-c2cncc(N[C@H](C)c3ccccc3)n2)ccc1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.65
LDHA P00338 2/20 0.61
LDHB P07195 2/20 0.61
CCNT1 O60563 4/20 0.56
CDK9 P50750 4/20 0.56
FYN P06241 1/20 0.55
CCNC P24863 1/20 0.53
CDK8 P49336 1/20 0.53
PFKFB3 Q16875 2/20 0.48
JAK2 O60674 1/20 0.47
JAK3 P52333 1/20 0.47
PLK1 P53350 1/20 0.45
BRAF P15056 2/20 0.44
ATP1A1 P05023 1/20 0.44
ATP1B1 P05026 1/20 0.44
ATP1A3 P13637 1/20 0.44
ATP1B2 P14415 1/20 0.44
ATP1A2 P50993 1/20 0.44
ATP1B3 P54709 1/20 0.44
FXYD2 P54710 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5208442 1.00 CSF1R (0.65) CSF1RLDHALDHBCCNT1CDK9
SCHEMBL18286643 0.91 CSF1R (0.60) CSF1RLDHALDHBCCNT1CDK9
SCHEMBL5208910 0.90 CSF1R (0.67) CSF1RLDHALDHBCCNT1CDK9
SCHEMBL5934776 0.90 FYN (0.67) CSF1RLDHALDHBCCNT1CDK9
SCHEMBL5205401 0.90 CSF1R (0.59) CSF1RLDHALDHBCCNT1CDK9
SCHEMBL5208271 0.90 FYN (0.67) CSF1RLDHALDHBCCNT1CDK9
SCHEMBL19447150 0.88 CSF1R (0.71) CSF1RLDHALDHBCCNT1CDK9
SCHEMBL12104596 0.88 CSF1R (0.66) CSF1RLDHALDHBCCNT1CDK9
SCHEMBL12104619 0.88 PFKFB3 (0.61) CSF1RLDHALDHBCCNT1CDK9
SCHEMBL12056826 0.86 CCNC (0.58) CSF1RLDHALDHBCCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513821-B1 PROTEIN KINASE INHIBITORS CYTOPIA PTY LTD (AU) 2007-10-31 EP disclosed
US-7122550-B2 Protein kinase inhibitors CYTOPIA PTY LTD (AU) 2006-10-17 US disclosed
US-20060148824-A1 Protein kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2006-07-06 US disclosed
US-20040235862-A1 For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235862-A1 For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer LCK, IRAK1, MAP2K5 CSF1R 1399/4885LDHA 3998/4885LDHB 4007/4885
US-20060148824-A1 Protein kinase inhibitors MAP3K20, MAP4K2, MAP3K1 CSF1R 3034/4885LDHA 3298/4885LDHB 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.